Grant Funds Development of a Novel Malaria Vaccine
iQur and the Edward Jenner Institute for Vaccine Research announced that that they will receive a grant of 152,000 EUR ($201,523) from the Technology Strategy Board's Biocatalyst fund to develop a novel malaria vaccine.
iQur, the UK biotechnology company, and the Edward Jenner Institute for Vaccine Research (University of Oxford) announced that that they will receive a grant of £152,000 ($201,523) from the Technology Strategy Board’s Biocatalyst fund to develop a novel malaria vaccine. The parties to develop a novel virus-like particle (VLP) based vaccine using iQur’s proprietary tandem core technology.
A proof of concept study will be carried out in which iQur will make VLPs carrying specific malaria targets that have been identified by the Jenner. If the project is successful, further funding will be sought to progress the targets into a clinical trial.
Source: iQur
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
